Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
Won Young Tak(Kyungpook National University Hospital), Masatoshi Kudo(Kindai University), Hisashi Hidaka(Kitasato University), Rina Hara(Yakult Honsha (Japan)), Masafumi Ikeda(National Cancer Center Hospital East), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Sojiro Morita(University of Kochi), Eishiro Mizukoshi(Kanazawa Medical University), Jeong Heo(National Cancer Center), Baek‐Yeol Ryoo(Asan Medical Center), Takeshi Aramaki(Shizuoka Cancer Center), Junji Furuse(Kanagawa Prefectural Hospital Organization), Takuji Okusaka(National Cancer Centre Japan), Osamu Nakamura(Wind Power Engineering (Japan)), Tae‐You Kim(Seoul National University of Science and Technology), Do Young Kim(Yonsei University), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Kazuhiro Katayama(Osaka International Cancer Institute), Takuya Kimura(Yakult Honsha (Japan)), Yasunori Kawaguchi(Saga-Ken Medical Centre Koseikan), Kohichiroh Yasui(Kyoto Prefectural University of Medicine), Jong-Eun Yeon(Korea University Medical Center), Ho Yeong Lim(CHA University Bundang Medical Center)
Cited by 49
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
|Nature Cell Biology|2000|1.6k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k